Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

April 3, 2019

NGM Bio Announces Pricing of Initial Public Offering

March 20, 2019

NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer

March 20, 2019

Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

January 3, 2019

Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 5 - 8 of 8

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2019 NGM Biopharmaceuticals, Inc..

All Rights Reserved.

Privacy Policy.

Top